ReviewFrontiers in endocrinology2025
White adipose tissue browning and peroxisome proliferator activated receptors in MASLD.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review.Journal of endocrinological investigation · 2026Review
- Metabolic signatures and machine learning identify gut-liver-heart axis dysfunction as a potential link to major adverse cardiovascular events in coronary artery disease.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Adipose Tissue Browning in MASLD and Its Molecular Mechanisms and Metabolic Crosstalk.Current obesity reports · 2026Review
- Review
- Alternative Receptor Signaling for the Selective and Multifaceted Regulation of Human Brown Adipocytes.International journal of molecular sciences · 2026Review
- Dysregulation of the Gut-Adipose Tissue-Liver Axis: a Possible Mechanism Behind the Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes.Current diabetes reports · 2026Review
- Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions.Food science & nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction associated steatotic liver disease (MASLD) has emerged as the predominant global etiology of chronic liver disease, with its incidence and prevalence continuously rising amid the obesity epidemic. The human body contains two primary types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). The process of adipose tissue browning refers to the phenomenon wherein WAT acquires BAT like characteristics under specific conditions, leading to the generation of beige adipocyte clusters within WAT. This process is critically linked to metabolic diseases such as MASLD. Peroxisome proliferator activated receptors (PPARs) constitute a class of nuclear receptor proteins that function as transcription factors to regulate gene expression. PPARs play pivotal roles in adipose tissue biology, particularly in the process termed adipose tissue browning. These functions of PPARs have garnered significant attention due to their potential as therapeutic targets for MASLD and metabolic syndromes, including obesity, diabetes, and dyslipidemia. PPARs may exert therapeutic effects on MASLD by promoting white adipose tissue browning; however, this mechanism lacks robust clinical evidence, and the safety profile of PPAR agonists requires further comprehensive evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.